Gyre : Phase 3 Trial Of Hydronidone In Chronic Hepatitis B Meets Main Goal; Prices $20 Mln Offering
23/5 03:53
(RTTNews) - Gyre Therapeutics (GYRE) announced that its lead compound, Hydronidone (F351), met the primary endpoint in a pivotal Phase 3 trial evaluating its efficacy and safety for the treatment of liver fibrosis in patients with chronic hepatitis B (CHB) in China....